Neurocrine Biosciences | NBIX - PE Price to Earnings


Neurocrine Biosciences reported 28.09 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
ALKERMES 39.33 19.8 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amgen 19.84 5.47 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Exelixis 13.91 588.4 Mar/2026
Gilead Sciences 17.7 2.07 Mar/2026
Halozyme Therapeutics 11.35 11.8 Mar/2026
Incyte 15.35 0.51 Mar/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Neurocrine Biosciences 28.09 807.38 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Prothena 22.11 11.37 Mar/2022
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Repligen 109.48 54.58 Mar/2026
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Sarepta Therapeutics 27.27 0 Dec/2025
Teva Pharmaceutical Industries 10.07 0.04 Mar/2026
Vertex Pharmaceuticals 25.82 0.33 Mar/2026